Xiaoyan Li

机构：Beijing Tian Tan Hospital, First Affiliated Hospital of Zhengzhou University, Shanghai Children's Hospital · ORCID：0000-0002-0490-7270

发表论文 54 篇 · 总被引 256 次 · h-index 10

代表论文

• Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer (2019 · Cancer Immunology Immunotherapy · 被引 45)
• Soluble programmed death‐1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B (2018 · Journal of Viral Hepatitis · 被引 31)
• Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors. (2024 · Journal of Clinical Oncology · 被引 22)
• Safety and efficacy of surgery combined with bleomycin irrigation for complex cervical–facial lymphatic malformations of children (2019 · International Journal of Pediatric Otorhinolaryngology · 被引 19)
• The Management of Giant Cerviofacial Lymphatic Malformations in Children (2019 · Journal of Craniofacial Surgery · 被引 19)
• Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies (2025 · Signal Transduction and Targeted Therapy · 被引 14)